Skip to main content

Table 5 Study design of the four meta-analysed prospective, open, randomised clinical studies in female patients with acute uncomplicated and recurrent cystitis treated with nitroxoline (NTX) versus a control antibiotic, cotrimoxazole (CTX) or norfloxacin (NFX)

From: Review of the literature and individual patients’ data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections

Study Nitroxoline Control Indication Patients (n) Duration End of therapy visit Test of cure visit
NWNF 10° Nitroxoline (NTX) Cotrimoxazole (CTX) Acute uncompl. cystitis 130 total 5 days day 6 day 12–14
3×250 mg 2×960 mg   67 NTX, 63 CTX
NWNF 11 Nitroxoline (NTX) Cotrimoxazole (CTX) Acute uncompl. cystitis 115 total 5 days day 6 day 12–14
3×250 mg 2×960 mg   56 NTX
59 CTX
NWNF 13 Nitroxoline (NTX) Norfloxacin (NFX) Acute uncompl. cystitis 105 total 5 days day 6 day 12–14
3×250 mg 2×400 mg   51 NTX
54 NFX
NWNF 15 Nitroxoline (NTX) Cotrimoxazole (CTX) Acute episode of uncompl. recurrent cystitis 116 total 10 days day 11–13* day 21–23
3×250 mg 2×960 mg 60 NTX
56 CTX
  1. °inclusion criteria missing (no urine cultures reported): total 12, NTX 7, CTX 5 patients (included in safety set only).
  2. *additional visit during therapy: day 6–8.